Utilization of sperm cryopreservation in patients with testicular cancer.
Cancer survivor
Cryopreservation
Infertility
Sexual quality of life
Sperm bank
Testicular cancer
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
17 Apr 2024
17 Apr 2024
Historique:
received:
12
02
2024
accepted:
23
03
2024
medline:
18
4
2024
pubmed:
17
4
2024
entrez:
17
4
2024
Statut:
epublish
Résumé
We assessed factors that affect the utilization of sperm cryopreservation before 2021, when patients covered expenses, and the influence on quality of life. Between 2011 and 2021, testicular cancer survivors (TCS) at our clinic completed a questionnaire, including EORTC QLQ-TC26, covering sperm cryopreservation, sociodemographic details, post-treatment births, and artificial insemination. After 5.7 ± 3.0 years, 279 participants (64%) responded to the questionnaire. Among them, 33% (91/279) of testicular cancer survivors chose sperm cryopreservation prior to treatment, with 11% (10/91) using it for insemination. Conversely, 2% (3/188) without cryopreservation reported unfulfilled desire to have children. Univariate analysis showed TCS with cryopreservation were younger (30.6 ± 7.1 (35 (21-59)) vs. 42.4 ± 10.9 (48 (22-81)) years; p = 0.001), had a lower BMI (24.2 ± 3.3 vs. 26.6 ± 4.6 kg/m Age and education seem to impact the choice of undergoing paid sperm cryopreservation. Urologists should inform testicular cancer patients about costs and coverage. Importantly, the occurrence of unmet desires for parenthood is minimal among those who forego cryopreservation.
Identifiants
pubmed: 38630148
doi: 10.1007/s00432-024-05725-2
pii: 10.1007/s00432-024-05725-2
pmc: PMC11024033
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
201Informations de copyright
© 2024. The Author(s).
Références
Int J Urol. 2021 Oct;28(10):1047-1052
pubmed: 34278620
Healthcare (Basel). 2021 May 09;9(5):
pubmed: 34065091
Reprod Biomed Online. 2012 Mar;24(3):321-30
pubmed: 22285245
J Oncol Pract. 2016 May;12(5):465-71
pubmed: 27118159
Eur J Cancer Care (Engl). 2020 Sep;29(5):e13279
pubmed: 32567091
Fertil Steril. 2006 Mar;85(3):640-5
pubmed: 16500332
Support Care Cancer. 2015 Sep;23(9):2763-8
pubmed: 25680764
Medicine (Baltimore). 2018 Sep;97(37):e12390
pubmed: 30213007
Eur J Pediatr. 2020 Jan;179(1):51-60
pubmed: 31493021
Reprod Biomed Online. 2016 Jul;33(1):29-38
pubmed: 27156003
Curr Opin Urol. 2000 Sep;10(5):473-7
pubmed: 11005454
Gynecol Oncol Rep. 2021 Feb 10;36:100716
pubmed: 33665292
J Clin Oncol. 1999 Jan;17(1):173-9
pubmed: 10458231
J Cancer Res Clin Oncol. 2023 Jul;149(8):5321-5330
pubmed: 36418559
Expert Rev Anticancer Ther. 2014 May;14(5):487-9
pubmed: 24506112
J Clin Oncol. 1997 Apr;15(4):1444-8
pubmed: 9193338
Cancer. 2015 Oct 1;121(19):3499-506
pubmed: 26214755
J Adolesc Young Adult Oncol. 2020 Feb;9(1):55-62
pubmed: 31621493
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
J Clin Oncol. 2002 Apr 1;20(7):1880-9
pubmed: 11919248
Biopreserv Biobank. 2019 Dec;17(6):603-612
pubmed: 31429586
Cancer. 2005 Aug 1;104(3):521-4
pubmed: 15968690
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Cancer. 2004 Feb 15;100(4):732-7
pubmed: 14770428
J Urol. 1996 Nov;156(5):1656-8
pubmed: 8863564